Search research articles
Contact Us
Filters
Showing results (81-90 of 98) with videos related to
Page
of 10
Sort By:
Advances in Therapy
|
November 21, 2025
Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A Inhibitors
Philip J Mease, Jessica A Walsh, Timothy P Fitzgerald, et al.
BMC Rheumatology
|
May 21, 2024
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study
Alexis Ogdie, Joseph F Merola, Philip J Mease, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2017
Clinical and molecular characterization of patients with cancer of unknown primary in the modern era
A M Varghese, A Arora, M Capanu, et al.
Trials
|
March 19, 2025
Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial
Alexis Ogdie, Soumya M Reddy, Sarah H Gillespie, et al.
Drug Safety
|
October 31, 2023
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis
Bruce Strober, Laura C Coates, Mark G Lebwohl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 24, 2018
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
J Mateo, D Chakravarty, R Dienstmann, et al.
RMD Open
|
March 17, 2022
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies
Christopher T Ritchlin, Philip J Mease, Wolf-Henning Boehncke, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
October 12, 2020
Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis
Iain B McInnes, Proton Rahman, Alice B Gottlieb, et al.
Trials
|
September 5, 2022
Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial
Dafna D Gladman, Philip J Mease, Paul Bird, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
January 22, 2024
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis
Stefan Siebert, Laura C Coates, Georg Schett, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 98) with videos related to
Sort By:
Page
of 10
Advances in Therapy
|
November 21, 2025
Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A Inhibitors
Philip J Mease, Jessica A Walsh, Timothy P Fitzgerald, et al.
BMC Rheumatology
|
May 21, 2024
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study
Alexis Ogdie, Joseph F Merola, Philip J Mease, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2017
Clinical and molecular characterization of patients with cancer of unknown primary in the modern era
A M Varghese, A Arora, M Capanu, et al.
Trials
|
March 19, 2025
Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial
Alexis Ogdie, Soumya M Reddy, Sarah H Gillespie, et al.
Drug Safety
|
October 31, 2023
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis
Bruce Strober, Laura C Coates, Mark G Lebwohl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 24, 2018
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
J Mateo, D Chakravarty, R Dienstmann, et al.
RMD Open
|
March 17, 2022
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies
Christopher T Ritchlin, Philip J Mease, Wolf-Henning Boehncke, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
October 12, 2020
Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis
Iain B McInnes, Proton Rahman, Alice B Gottlieb, et al.
Trials
|
September 5, 2022
Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial
Dafna D Gladman, Philip J Mease, Paul Bird, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
January 22, 2024
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis
Stefan Siebert, Laura C Coates, Georg Schett, et al.
Page
of 10